- Home
- VRNA
VRNA
Verona Pharma plc
as 12-17-2024 4:00pm EST
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 3.2B | IPO Year: | 2017 |
| Target Price: | $43.83 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.39 - $43.73 | Next Earning Date: | 11-04-2024 |
| Revenue: | $5,624,000 | Revenue Growth: | 1127.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 644.06% |
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | VRNA | President and CEO | Nov 27 '24 | Sell | $5.00 | 125,328 | $627,233.33 | 15,075,424 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Nov 27 '24 | Sell | $5.00 | 113,240 | $566,821.84 | 14,175,696 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Nov 25 '24 | Sell | $5.00 | 2,400 | $12,000.00 | 14,175,696 | |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | Nov 25 '24 | Sell | $4.90 | 240,000 | $1,176,360.00 | 2,671,480 | |
| EBSWORTH DAVID R | VRNA | Director | Nov 18 '24 | Buy | $4.44 | 20,000 | $88,800.00 | 940,003 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Nov 11 '24 | Sell | $5.00 | 2,400 | $12,000.00 | 15,075,424 | |
| Hahn Mark W | VRNA | Chief Financial Officer | Nov 11 '24 | Sell | $5.00 | 2,400 | $12,000.00 | 14,175,696 | |
| EBSWORTH DAVID R | VRNA | Director | Nov 6 '24 | Buy | $4.80 | 39,360 | $188,880.77 | 940,003 | |
| ACKERMANN CHRISTINA | VRNA | Director | Nov 6 '24 | Buy | $4.74 | 41,880 | $198,385.56 | 41,880 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | Nov 1 '24 | Sell | $4.38 | 141,032 | $618,657.57 | 15,075,424 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
MT Newswires
21 days ago
Verona Pharma Insider Sold Shares Worth $1,176,360, According to a Recent SEC Filing
GlobeNewswire
a month ago
Verona Pharma Announces December 2024 Investor Conference Participation
MT Newswires
a month ago
Verona Pharma Insider Sold Shares Worth $568,387, According to a Recent SEC Filing
MT Newswires
a month ago
Verona Pharma Insider Sold Shares Worth $618,658, According to a Recent SEC Filing
Simply Wall St.
a month ago
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years
GuruFocus.com
a month ago
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
GlobeNewswire
a month ago
Verona Pharma to Present at Jefferies London Healthcare Conference
MT Newswires
a month ago
Verona Pharma's Q3 Loss Widens
Compare VRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRNA Verona Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.